Refacto | Tomguy

Refacto AF / Pfizer

Deliverables: Present Refacto's competitive claims in three compelling options for client review

ReFacto AF treats and prevents patients with Haemophilia A—a rare, inherited bleeding disorder in adolescents. Refacto's competitive claim is its purification process which minimizes the rate of therapy rejection. Preferred Option: “Stepping Up” plays on Refacto's technical feats and what that means for the patient.

Second Option: Explores the frustration of the patient who resent the severe lifestyle restrictions imposed by overly cautious parents and physicians. Refacto resolves the high rate of therapy reaction (i.e., poor drug reaction) of other drugs.

The “Client-Ask” Option completes the range by hero-ing the technical claims favored by Refacto's field reps.